- Home
- SGLY vs LEXX Comparison
SGLY vs LEXX Comparison
Compare SGLY & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | LEXX |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 9.5M |
| IPO Year | 2008 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SGLY | LEXX |
|---|---|---|
| Price | $0.43 | $4.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 38.8K |
| Earning Date | 11-24-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,693,264.00 | $705,923.00 |
| Revenue This Year | $2,964.44 | N/A |
| Revenue Next Year | N/A | $6,915.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.23 | $0.35 |
| 52 Week High | $8.65 | $21.60 |
Technical Indicators
Market Signals| Indicator | SGLY | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 62.09 |
| Support Level | $0.27 | $2.67 |
| Resistance Level | $0.59 | $10.26 |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | 0.05 | 0.25 |
| Stochastic Oscillator | 51.27 | 89.53 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.